Loading stock data…
UTHR
$570.40-0.95 (-0.17%)
Market ClosedLast close May 1
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
United Therapeutics Corporation in the Healthcare sector is trading at $570.40. The stock is currently near its 52-week high of $607.89, remaining 25.3% above its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why UTHR maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$570.40
Potential Upside
4.5%
Whystock Fair Value$596.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$644.62+13.0%
Range$519.00 – $733.00
Fundamentals
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$25.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.57
Beta
Defensive asset. Lower volatility than the S&P 500.
0.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.50%
Volume
Today's trading volume
186,136
Recent News
Assessing United Therapeutics (UTHR) Valuation After A Strong Multi Year Share Price Run
Why United Therapeutics Is On Investors’ Radar United Therapeutics (UTHR) is drawing attention after a period of strong share performance, with the stock showing a 94% total return over the past year and 166% over the past 3 years. At a recent close of US$570.40 and a market cap of about US$25.0b, the company combines sizeable scale with positive annual revenue and net income growth. This is leading some investors to reassess its current valuation. See our latest analysis for United...
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty
MannKind’s fair value estimate has been trimmed from US$7.50 to about US$7.17, a modest cut of roughly 4% that signals a slightly more cautious stance in updated models. This shift lines up with recent analyst commentary, where several firms have lowered price targets and at least one has moved to a more neutral rating as they reassess Tyvaso DPI royalties and the implications of United Therapeutics' soft mist inhaler plans. As you read on, you will see how both bullish and bearish voices are...
CPRX or UTHR: Which Is the Better Value Stock Right Now?
CPRX vs. UTHR: Which Stock Is the Better Value Option?